๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Advances in shotgun proteomics and the analysis of membrane proteomes

โœ Scribed by Joshua M. Gilmore; Michael P. Washburn


Publisher
Elsevier
Year
2010
Tongue
English
Weight
571 KB
Volume
73
Category
Article
ISSN
1874-3919

No coin nor oath required. For personal study only.

โœฆ Synopsis


The emergence of shotgun proteomics has facilitated the numerous biological discoveries made by proteomic studies. However, comprehensive proteomic analysis remains challenging and shotgun proteomics is a continually changing field. This review details the recent developments in shotgun proteomics and describes emerging technologies that will influence shotgun proteomics going forward. In addition, proteomic studies of integral membrane proteins remain challenging due to the hydrophobic nature in integral membrane proteins and their general low abundance levels. However, there have been many strategies developed for enriching, isolating and separating membrane proteins for proteomic analysis that have moved this field forward. In summary, while shotgun proteomics is a widely used and mature technology, the continued pace of improvements in mass spectrometry and proteomic technology and methods indicate that future studies will have an even greater impact on biological discovery.


๐Ÿ“œ SIMILAR VOLUMES


Evaluation and optimization of removal o
โœ Yong Lin; Yi Liu; Jianjun Li; Yan Zhao; Quanze He; Wenjun Han; Ping Chen; Xianch ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 332 KB

## Abstract Due to its compatibility with protease activity at high concentration, sodium deoxycholate (SDC) can be used to effectively improve the solubilization and enzymolysis of membrane proteins and has received increasing attention in the field of membrane proteome analysis in recent years. S

In vivo pharmaco-proteomic analysis of h
โœ Swati S. Ghatpande; Pankaj K. Choudhary; Charles T. Quinn; Steven R. Goodman ๐Ÿ“‚ Article ๐Ÿ“… 2010 ๐Ÿ› Elsevier ๐ŸŒ English โš– 519 KB

Hydroxyurea (HU) is an effective drug for the treatment of sickle cell disease (SCD). The main clinical benefit of HU is thought to derive from its capacity to increase fetal hemoglobin (HbF) production. However, other effects leading to clinical benefit, such as improved blood rheology, have been s